Effect of clonidine on myocardial cyclic GMP content in the mouse-activation of central and peripheral alpha adrenoceptors

• Published in: The Journal of pharmacology and experimental therapeutics Vol. 251; no. 3; pp. 884 - 887
• Main Authors: VULLIEMOZ, Y, VEROSKY, M
• Format: Journal Article
• Language: English
• Published: Bethesda, MD American Society for Pharmacology and Experimental Therapeutics 01.12.1989
• Subjects: alpha -adrenergic; Animals; Biological and medical sciences; Brain - drug effects; Catecholaminergic system; clonidine; Clonidine - analogs & derivatives; Clonidine - pharmacology; cyclic GMP; Cyclic GMP - analysis; effects on; Hexamethonium; Hexamethonium Compounds - pharmacology; levels; Male; Medical sciences; Mice; Myocardium - analysis; Neuropharmacology; Neurotransmitters. Neurotransmission. Receptors; Pharmacology. Drug treatments; receptors; Receptors, Adrenergic, alpha - drug effects; Receptors, Muscarinic - drug effects; Heart; Intraperitoneal administration; Rodentia; Nervous system; Adrenergic transmission; Dose activity relation; Vertebrata; Biological fixation; Mammalia; Mouse; Animal; Antihypertensive agent; Muscarinic receptor; α-Adrenergic receptor agonist; Circulatory system; Mechanism of action; α2-»Adrenergic receptor
• ISSN: 0022-3565; 1521-0103

Clonidine (0.23-3.77 mumol/kg i.p.) produced a dose-dependent increase in mouse myocardial cyclic GMP (cGMP) content. This effect was antagonized by yohimbine (0.03-1 mg/kg i.p.), but not by prazosin (1 mg/kg i.p.). The inhibition by yohimbine was biphasic. The cGMP response to clonidine was inhibited by atropine (5 mg/kg i.p.) and methylatropine (0.2-5 mg/kg i.p.). In mice pretreated with the ganglionic blocker hexamethonium, the cGMP response to clonidine persisted. St-91 [(2,6-diethylphenylamino)-2-imidazoline] (0.39-3.94 mumol/kg i.p.), a cogener of clonidine which does not cross the blood-brain barrier, also increased myocardial cGMP content. The potency of clonidine was similar in mice pretreated and nonpretreated with hexamethonium. Methylatropine did not affect the cGMP response to St-91 and to clonidine in ganglionectomized mice and yohimbine was a less potent antagonist. These results indicate that systemic administration of clonidine produces an increase in myocardial cGMP content by both a central and a peripheral action. The increase in cGMP can be due to a direct activation of cardiac prejunctional alpha-2 adrenoceptors and to stimulation of cardiac muscarinic receptors, a response secondary to an action of clonidine on central alpha-2 adrenoceptors.